The Role of CSF in Alzheimer’s Disease



Cerebrospinal fluid (CSF) has been used in research on Alzheimer’s disease for decades, but only recently have the platforms been developed to standardize measurements across laboratories. CSF data from the Mayo Clinic Study of Aging and the Mayo Clinic Alzheimer’s Disease Research Center have been analyzed on the Roche Elecsys platform and will be discussed in the context of aiding in the diagnosis of Alzheimer’s disease.


Ronald Petersen, M.D., Ph.D.
Professor of Neurology
Mayo Clinic, Rochester, Minnesota

Learning Objectives

Upon completion of this activity, participants should be able to:

  • List the criteria for diagnosing Alzheimer’s disease.
  • Discuss the validation of CSF markers for Alzheimer’s disease.
  • Identify the limitations of CSF testing for Alzheimer’s disease.

Intended Audience

This webinar is designed for any provider who sees patients with neurologic diseases (e.g., neurologists, psychiatrists, and primary care physicians, including internists and family care practitioners) as well as pathologists, laboratory directors, and laboratory send-out coordinators.

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Learn more about our testing


Contact us:

MCL Education

This post was developed by our Education and Technical Publications Team.